# Edoxaban for TIA and Acute Minor Stroke

Study · id `cardio:ct-nct02221102` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02221102](<https://clinicaltrials.gov/study/NCT02221102>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02221102

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3700 participants.

## Technical summary

Registry record NCT02221102. Randomized; triple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 3700 participants (planned count; ClinicalTrials.gov record NCT02221102, source copy `cardio:ctgov-nct02221102-2014-08-20`, retrieved 2026-10-26)
- Start date: 2013-12 (registry gives no type) (ClinicalTrials.gov record NCT02221102, source copy `cardio:ctgov-nct02221102-2014-08-20`, retrieved 2026-10-26)
- Primary completion: 2015-06 (anticipated) (ClinicalTrials.gov record NCT02221102, source copy `cardio:ctgov-nct02221102-2014-08-20`, retrieved 2026-10-26)
- Completion: 2016-06 (anticipated) (ClinicalTrials.gov record NCT02221102, source copy `cardio:ctgov-nct02221102-2014-08-20`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02221102, source copy `cardio:ctgov-nct02221102-2014-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02221102-2014-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Edoxaban for TIA and Acute Minor Stroke
- Condition: Ischemia
- Condition: Stroke
- Condition: Cerebral Infarction
- Intervention (Drug): Aspirin
- Intervention (Drug): edoxaban
- Intervention (Drug): placebo
- Lead sponsor: Xijing Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Edoxaban (`cardio:edoxaban`)
- Registry lists this organization as the lead sponsor: Xijing Hospital (`cardio:org-xijing-hospital`)

## Provenance

Content hash: d710117e2aa45106368bc0b1f3ce0aeb2823c6ca65f97c5336669ef3b1f9f59b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
